{"name":"iRegene Therapeutics Co., Ltd.","slug":"iregene-therapeutics-co-ltd","ticker":"","exchange":"","domain":"iregene.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Human Dopaminergic Progenitor Cells","genericName":"Human Dopaminergic Progenitor Cells","slug":"human-dopaminergic-progenitor-cells","indication":"Parkinson's disease","status":"phase_2"}]}],"pipeline":[{"name":"Human Dopaminergic Progenitor Cells","genericName":"Human Dopaminergic Progenitor Cells","slug":"human-dopaminergic-progenitor-cells","phase":"phase_2","mechanism":"Dopaminergic progenitor cells are thought to replace or repair dopamine-producing neurons in the brain.","indications":["Parkinson's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1IWGt0aHk5LV9Ra2l3Z2FqQXB5am1RODZZaVIydHJvM2ZMX2R6bFJ4R0VGWjAwU25CdkYzY1VocnAwcGpTcnJTNXhYVU9zanB6Sk5pbE9NVk1OMURLeHM3VEdkWGRlcnPSAWxBVV95cUxOV05WRWNUVmU1Zy1QRzNXQlBwQjlUb2xieU91ekx1SmNQcXEwQ2dxVkxtaThLd21uUzFiaE1pWEVZVVJ3dUQ1RjNTelpyb3hyLVlHa3ZyT3Y5c0ZTQUM2MFRaTFNEYkp2X2E0N3c?oc=5","date":"2026-03-05","type":"pipeline","source":"BioInformant","summary":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant","headline":"The Pipeline for iPSC-Derived Cell Therapeutics in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPUUdfZmpUb29DNEVld3VxWG0waGNSd3pubUg2a21jMS0taUNTZG1ZdTRyRXc5REVhS0hPUXpUSE5YcnJ4UWpZcVVSTHREOGgzTVZVNVE5NXFFTGdaamtMdFU0WFhNSmFoaS0yUGNhOUtsQzgzWlJSNWFNVlZGbXlySVVMTFJrZmVwTTR2TGN3?oc=5","date":"2026-01-20","type":"regulatory","source":"Pharmaceutical Technology","summary":"iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s - Pharmaceutical Technology","headline":"iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPLTNXalpCbmtmNUJOYUVCVG1IU25WZDdiOXB6Ymc1bDZsS2VvRkxrSi1YUUVmbjJiUjNCMFZFRUNoTW1jZ0pmNGlTSUVwejZEUU5yRnR6OGFHZ3VLRGNIUlJIUW5hWWtGcTR2YURSOWlFM2xBWTNadmhkSDlKQ2hlR183MVRVOFBVNldubm1fQUprNWFreTRmN08xLXhwR3QxSGZtcFZYNXc2Ny1OZ0JqVEUwT3ppV2NRV3JXbTFFNnEtQU5JRkxRbzd5NUtGNTNDdS1GRHotMzFSMjRsSVdNNVE4ZTVyY1JHN3ZtcTI4OA?oc=5","date":"2025-09-10","type":"pipeline","source":"BioPharma APAC","summary":"iRegene Secures Over RMB 300 Million in Landmark Series B+ Financing to Advance First-in-Class iPSC Cell Therapies - BioPharma APAC","headline":"iRegene Secures Over RMB 300 Million in Landmark Series B+ Financing to Advance First-in-Class iPSC Cell Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPalRTSkhoVmNpS3FsZEYzNVI5OVRqWXRBYnczSG02LVk0VzB3S2VfcUtBMmROWXpNdHo5VV9Wc2J2akE3dVY1Mk1KSUZaelhHYXI3TmM4dDdIN1F5RDlORE9jWjhxUFlDb29VX1hCWXpFeHFPQVkxdzJKRk1raDN4aGY1MklWZnhQUTc3SjlWaElqMGc?oc=5","date":"2025-06-08","type":"pipeline","source":"Yahoo Finance","summary":"Frost & Sullivan: iRegene Therapeutics Honored as \"2025 Forbes China Leading Enterprises in Industry Development\" - Yahoo Finance","headline":"Frost & Sullivan: iRegene Therapeutics Honored as \"2025 Forbes China Leading Enterprises in Industry Development\"","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxQUGx5Nnc2U2laS20yUFdZSFh3ekpCN2Y2aUI0M1pPajZnYVlySy1RTktGRzBEUmlGay04c0hWUDN0Tm9WWGF4dVMxdlpEX2FMLWhVSHd3N1c4bWxuMkRyck91Z1hSeVBmS2pkQ0U2dnpDb2VXVF9yNERJUTBIZEFBY2tyNUpVWm5wdmNVQUdqbzc1S0pNUmlRQ2tKWFNuTjJyUWtVblRpaEtSV3lIWE1ZSFZSaFRWMi05NEk3VE9MLUZ4U2VkSDN4UTlwQkZxeXJsZnVIM0ZxWjh4STZfM2puRDhGZTI1Rmg5YlFrVHk1WnZxaGVldjNpTDJKZUxsRVEyX1FFeVVnQXdveTJ1RHdBalBxcTN0LUYyelhINXhHLWtaMG4wSnFBSnd4Q0dJbTJsckVvN2NCbEw4VG1lSndldTlEajZDOTZTb2hBQm1ybGxMU1pwSmI1RWkxd192aldTNGc?oc=5","date":"2024-10-09","type":"trial","source":"PR Newswire","summary":"Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - PR New","headline":"Cell and Gene Therapy in Parkinson's Disease Clinical Trial Pipeline Analysis Demonstrates 18+ Key Companies at the Hori","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMGNRSk5HbVNsVVBPQ2JlMno0Q3JlckJwRGlhRU04Ql80QXZrLXIzRk1sU3RJaHdPamFNTGZVWTI3VmE1QlZpVkJIdi1wV184ak1nZlFpX05hdGRiUGRqSVByeXJNd3JGMWhRZC13aHcxX1ZfX1BKXzY2Wl8tekRERVNqSjdUdjFoR1haS1IzVE45b2Y2bnJNNllodEFJUWVVTVF4UkZjeUNGWm9IQzZr?oc=5","date":"2023-07-31","type":"pipeline","source":"KPMG","summary":"KPMG Private Enterprise Global Tech Innovator - KPMG","headline":"KPMG Private Enterprise Global Tech Innovator","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}